Bioequivalence of twice-daily oral tacrolimus in transplant recipients: More evidence for consensus?

Abstract

In this Perspective on the clinical trial by Rita Alloway and colleagues, Simon Ball explains the benefits to healthcare systems and individual patients of the bioequivalence established between generic and brand-name formulations of an immunosuppressive drug in transplant recipients.